poisar

Stocks · News reference

CRISPR Therapeutics Presents Positive Phase 1b Clinical Data for CTX310

Fiscal.ai

CRISPR Therapeutics reported clinical results from its Phase 1b trial of CTX310, an in vivo CRISPR/Cas9 gene editing therapy for severe hypertriglyceridemia, showing significant reductions in ANGPTL3 and triglyceride levels.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolBrendan Coffey

    Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

    The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.